ORASURE TECHNOLOGIES, INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ORASURE TECHNOLOGIES, INC (OSUR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.43 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-09
- ORASURE TECHNOLOGIES, INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.43, a 50.93% decline from fiscal 2024.
- ORASURE TECHNOLOGIES, INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.99, a 13.11% increase from fiscal 2023.
- ORASURE TECHNOLOGIES, INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $6.18, a 30.25% decline from fiscal 2022.
- ORASURE TECHNOLOGIES, INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.86, a 35.23% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $3.43 10-K · filed 2026-03-09 |
| 2024-12-31 | $6.99 10-K · filed 2025-03-07 |
| 2023-12-31 | $6.18 10-K · filed 2024-03-11 |
| 2022-12-31 | $8.86 10-K · filed 2023-03-03 |
| 2021-12-31 | $13.68 10-K · filed 2022-03-01 |
| 2020-12-31 | $7.16 10-K · filed 2021-03-01 |
| 2019-12-31 | $12.71 10-K · filed 2020-03-02 |
| 2018-12-31 | $20.35 10-K · filed 2019-02-28 |
| 2017-12-31 | $9.92 10-K · filed 2018-02-28 |
| 2016-12-31 | $6.00 10-K · filed 2018-02-28 |
| 2015-12-31 | $9.28 10-K · filed 2018-02-28 |
| 2014-12-31 | $5.77 10-K · filed 2017-03-14 |
| 2013-12-31 | $6.94 10-K · filed 2016-03-14 |
| 2012-12-31 | $11.18 10-K · filed 2015-03-12 |
| 2011-12-31 | $6.78 10-K · filed 2014-03-14 |
| 2010-12-31 | $5.15 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |